Taj Pharmaceuticals Ltd.

Cefotaxime Sodium

CAS No. : 64485-93-4.

Systematic (IUPAC) name

cefotaxime sodiumis a semisynthetic, broad spectrum cephalosporin antibiotic for parenteral administration. It is the sodium salt of 7-[2-(2-amino-4-thiazolyl) glyoxylamido]-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate 72 (Z)-(o-methyloxime), acetate (ester). CLAFORAN contains approximately 50.5 mg (2.2 mEq) of sodium per gram of cefotaxime activity. Solutions of CLAFORAN range from very pale yellow to light amber depending on the concentration and the diluent used. The pH of the injectable solutions usually ranges from 5.0 to 7.5.



The CAS Registry Number is 64485-93-4.

Indications and Usage

Treatment of infections of lower respiratory tract including pneumonia, urinary tract, skin and skin structures, bone and joints; treatment of bacteremia/septicemia, CNS infections, intra-abdominal infections including peritonitis, gynecological infections including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by susceptible strains of specific microorganisms; perioperative prophylaxis.

Side effects

Cefotaxime may cause side effects. If you are administering cefotaxime into a muscle, it may be mixed with lidocaine (Xylocaine) to reduce pain at the injection site. Tell your health care provider if any of these symptoms are severe or do not go away:

* diarrhea
* stomach pain
* upset stomach
* vomiting

If you experience any of the following symptoms, call your health care provider immediately:

* unusual bleeding or bruising
* difficulty breathing
* skin rash
* itching
* hives

* sore mouth or throat

Storage/Stability/Compatibility -

Cefotaxime sodium sterile powder for injection should be stored at temperatures of less than 30°C; protect from light. The commercially available frozen injection should be stored at temperatures no greater than -20°C. Depending on storage conditions, the powder or solutions may darken which may indicate a loss in potency.

Doses -

Horses:For susceptible infections:

a) Foals: 20 - 30 mg/kg IV q6h (Caprile and Short 1987)

Dosage Forms/Preparations/FDA Approval Status -

Veterinary-Approved Products: None

Human-Approved Products:

Cefotaxime Sodium Powder for Injection; 500 mg, 1 g (as cefotaxime), 2 g, 10

Cefotaxime Sodium for Injection in 5% dextrose bags (50 ml)—frozen; 1 g, 2 g;

Note /Government Notification: These chemicals are designated as those that are used in the manufacture of the controlled substances and are important to the manufacture of the substances. For any (Control Substance) products Import and Export *** subjected to your country government laws /control substance ACT.

Information: The information on this web page is provided to help you to work safely, but it is intended to be an overview of hazards, not a replacement for a full Material Safety Data Sheet (MSDS). MSDS forms can be downloaded from the web sites of many chemical suppliers. ,also that the information on the PTCL Safety web site, where this page was hosted, has been copied onto many other sites, often without permission. If you have any doubts about the veracity of the information that you are viewing, or have any queries, please check the URL that your web browser displays for this page. If the URL begins "www.tajapi.com/www/Denatonium Benzoate.htm/" the page is maintained by the Safety Officer in Physical Chemistry at Oxford University. If not, this page is a copy made by some other person and we have no responsibility for it.

The Controlled Substances Act (CSA) was enacted into law by the Congress of the United States as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970.[1] The CSA is the federal U.S. drug policy under which the manufacture, importation, possession, use and distribution of certain substances is regulated. The Act also served as the national implementing legislation for the Single Convention on Narcotic Drugs

This document plus the full buyer/ prescribing information, prepared for health professionals can be found at:
http://www.tajapi.com
or by contacting the sponsor, Taj Pharmaceuticals Limited., at:
91 022 30601000.
This leaflet was prepared by
Taj Pharmaceuticals Limited,
Mumbai (India).
MPSTJ278
Last revised: 29 August 2009